ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 49 citations in OpenAlex.
- Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Antimicrobial agents and chemotherapy · 2019Trial
- Role and plasticity of Th1 and Th17 responses in immunity toHuman vaccines & immunotherapeutics · 2019Trial
- Rationalizing Heterogeneity in Staphylococcus aureus Bacteremia: Current Progress and Future Goals.The Journal of infectious diseases · 2026Review
- Editorial for the Special Issue "Staphylococcal Biology and Pathogenesis".Antibiotics (Basel, Switzerland) · 2026Article
- Ultra-rapid nanoplasmonic colorimetry in microfluidics for antimicrobial susceptibility testing directly from specimens.Nature nanotechnology · 2026Article
- Detection of septic metastases in catheter-related Staphylococcus aureus bacteremia using 18BMC infectious diseases · 2025Article
- The lack of a biorepository during vaccine trials: A lost opportunity to understand staphylococcal immunity.Vaccine · 2025Article
- Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia.Annals of clinical microbiology and antimicrobials · 2025Article
- Pathobiont-induced suppressive immune imprints thwart T cell vaccine responses.Nature communications · 2024Article
- Clinical and microbiological characteristics of persistent Staphylococcus aureus bacteremia, risk factors for mortality, and the role of CD4Scientific reports · 2024Article
- The Complex Intracellular Lifecycle ofInternational journal of molecular sciences · 2024Review
- Determining the Prognostic Value of Complete Blood Count Subgroup Parameters inJournal of patient-centered research and reviews · 2024Article
- Anti-Alpha-Toxin Antibody Responses and Clinical Outcomes ofJournal of Korean medical science · 2023Article
- Article
- Biomarkers for differentiation of coronavirus disease 2019 or extracorporeal membrane oxygenation related inflammation and bacterial/fungal infections in critically ill patients: A prospective observational study.Frontiers in medicine · 2022Article
- Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Review
- Cell Membrane Adaptations Mediate β-Lactam-Induced Resensitization of Daptomycin-Resistant (DAP-R)Microorganisms · 2021Article
- Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia.BMC infectious diseases · 2021Article
- Comparison of Host Cytokine Response in Piglets Infected With Toxigenic and Non-toxigenicFrontiers in veterinary science · 2021Article
- The Binary Classification of Protein Kinases.Journal of inflammation research · 2021Article
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundCell wall peptidoglycan stimulates interleukin 10 (IL-10) production in Staphylococcus aureus bacteremia (SaB) animal models, but clinical data are not available. This study evaluates the impact of intravascular bacterial cell numbers (ie, the level of bacteremia), in patients at the time of clinical presentation on IL-10 production and its association with S. aureus bacteremia (SaB) mortality.
methodsBlood and isolates were collected in 133 consecutive SaB patients. Serum IL-10 was quantified by an electrochemoluminescence assay. Bacterial inoculum was measured in patient sera with elevated (n = 8) or low (n = 8) IL-10 using a magnetic bacterial capture assay. Staphylococcus aureus from these 2 groups were introduced into whole blood ex vivo to determine IL-10 production with variable inocula.
resultsIL-10 serum concentration was higher in SaB patient mortality (n = 27) vs survival (n = 106) (median, 36.0 pg/mL vs 10.4 pg/mL, respectively, P < .001). Patients with elevated IL-10 more often had endovascular SaB sources. The inoculum level of SaB was higher in patients with elevated serum IL-10 vs patients with low IL-10 (35.5 vs 0.5 median CFU/mL; P = .044). Ex vivo studies showed that 108 CFU/mL yielded greater IL-10 than did 103 CFU/mL (4.4 ± 1.8 vs 1.0 ± 0.6 pg/mL; P < .01).
conclusionsElevated IL-10 serum concentrations at clinical presentation of SaB were highly associated with mortality. High intravascular peptidoglycan concentration, driven by a higher level of bacteremia, is a key mediator of IL-10 anti-inflammatory response that portends poor clinical outcome. Using IL-10 as an initial biomarker, clinicians may consider more aggressive antimicrobials for rapid bacterial load reduction in high-risk SaB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.